Our History
Atley Solutions was founded on the pioneering research conducted by the Targeted Alpha Therapy Group (TAT Group) at the University of Gothenburg, Sweden.
Since the early 1990s, the TAT Group has been at the forefront of At-211 radiopharmaceutical research, with Atley’s scientific Co-Founders, Dr. Emma Aneheim and Dr. Sture Lindegren, playing key roles. Other notable members of the group include Dr. Tom Bäck, the inventor of the alpha camera, and Dr. Stig Palm, a globally recognized expert in radiopharmaceutical dosimetry
Leading the Way in At-211 Radiopharmaceuticals
In 2009, the TAT Group conducted the second-ever clinical trial using an At-211-based radiopharmaceutical. The trial aimed to evaluate the safety of an At-211-labeled antibody fragment (MX35-FAb2) for the treatment of metastatic ovarian cancer. The results were promising: no dose-limiting toxicity was observed, and although the sample size was small, signs of efficacy were evident. Remarkably, 25% of the treated women were still alive 10 years after enrollment.
To advance the clinical development of their radiopharmaceutical candidate, the team recognized the need for a scalable, GMP-compliant manufacturing method. This required technology that could not only enable production in Gothenburg, Sweden but also support global scalability. This challenge inspired Emma and Sture to develop the innovative automated manufacturing platform that now forms the backbone of Atley’s product and service offerings.
Founded in 2019, Atley Solutions has since emerged as the world leader in products and services for the development and manufacturing of At-211 radiopharmaceuticals. Our mission is to enable the development and commercialization of improved—and ultimately life-saving—treatments for metastatic cancer using At-211. Based in Sweden, Atley Solutions operates its headquarters and laboratory in Gothenburg, as well as a product development and manufacturing facility in Kristinehamn.